Precision BioSciences financials
$6.18−0.96%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $34.3M | $68.7M | $48.7M | $25.1M | $115.5M | $24.3M | $22.2M |
| Gross profit | $34.3M | $68.7M | $48.7M | $25.1M | $115.5M | $24.3M | $22.2M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$52.1M | -$26.2M | -$43.7M | -$73.2M | -$33.4M | -$109.8M | -$87.2M |
| Net income | -$45.7M | $7.2M | -$61.3M | -$111.6M | -$30.6M | -$109.0M | -$92.9M |
| Net margin | −133.4% | 10.4% | −125.8% | −444.8% | −26.5% | −448.9% | −417.6% |
| Diluted EPS | $-3.56 | $1.04 | $-15.96 | $-38.10 | $-15.60 | $-62.70 | $-66.30 |
| EBITDA | -$50.7M | -$22.8M | -$36.9M | -$53.3M | -$29.2M | -$100.0M | -$81.9M |
| Operating cash flow | -$65.8M | -$58.4M | -$84.1M | -$45.8M | -$10.9M | -$87.4M | -$71.0M |
| Free cash flow | -$65.9M | -$58.7M | -$86.1M | -$49.1M | -$15.9M | -$92.4M | -$95.7M |
| Diluted shares | 12.8M | 6.9M | 3.8M | 2.9M | 2.0M | 1.7M | 1.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $110.8M | $85.9M | $116.7M | $189.6M | $143.7M | $89.8M |
| Short-term investments | $4.8M | $413.0K | $0.00 | $0.00 | — | — |
| Total debt | $22.4M | $22.3M | $22.4M | $22.2M | $2.5M | $0.00 |
| Total assets | $154.4M | $136.4M | $159.8M | $238.2M | $211.5M | $150.2M |
| Total liabilities | $62.2M | $80.0M | $140.9M | $177.7M | $120.3M | $105.7M |
| Shareholders' equity | $92.2M | $56.4M | $18.9M | $60.4M | $91.2M | $44.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology